Supernus Pharmaceuticals Q3 2024 Earnings Report

Supernus Pharmaceuticals, Inc. (SUPN) reported strong financial results for Q3 2024 during its earnings call on November 4, 2024.
Total revenue surged to $175.7 million, up from $153.9 million YoY, driven by growth in key products Qelbree and GOCOVRI. Net product sales increased significantly to $170.3 million, with Qelbree prescriptions rising by 19% and GOCOVRI net sales up 8% year-over-year. Despite these successes, legacy products Trokendi XR and Oxtellar XR faced declining sales.

Key Takeaways

• Q3 revenue increased to $175.7 million.
• Net product sales accounted for $170.3 million.
• Qelbree prescriptions increased by 19%, achieving $62 million in net sales.
• GOCOVRI net sales rose by 8%, reaching $36 million.
• Trokendi XR sales declined by 26% to $15 million.
• Full-year 2024 revenue guidance is raised to $630 million – $650 million.
• Expected GAAP operating earnings of $50 million – $65 million for 2024.

Company Outlook

• Continued erosion in Trokendi XR sales is anticipated.
• Combined sales target for Trokendi XR and Oxtellar XR is set at $155 million for 2024.
• Positive expectations for new product launches and ongoing pipeline development.

Highlights

• Bullish: Growth in Qelbree and GOCOVRI, strong cash reserves at $403.2 million.
• Bearish: Trokendi XR sales decreasing by 26% and Oxtellar XR sales stagnant.
• Research shows SPN-817 achieved a 56% reduction in seizures.
• Anticipated FDA approval for the apomorphine pump by February 2025.

InvestingPro Insights

Supernus has shown a 6.79% growth in revenue over the past year, with a 14.17% increase recently. Despite challenges, cash reserves and profitability position it favorably for future growth.

Full Transcript Highlights

The call featured CEO Jack Khattar and CFO Tim Dec, discussing the company's positive trajectory despite losses in legacy products. Key points included increased product sales, R&D expense insights, and cash flow improvements supporting potential future M&A activities.

Supernus aims to maintain growth in its core products while expanding its pipeline, positioning itself against competitors and enhancing revenue prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.